circuitcity Thursday, 07/02/20 10:35:48 PM Re: massulo52 post# 284337 Post # of 301561 My view has been that generics don’t give V a fcuk actually. They have way too many drugs and this is just one. It is nice to wait for amrn to fully develop the market, but not a must. Saying above does not mean they will let amrn go easy esp they have won round 1. So V is useless to them but super important to amrn, so what does amrn has to do to get generics to settlement? Sounds like a blackmail, right? It is exactly what it is imo. So amrn has to share out the potential profit or patent period with them, 50% maybe too much, but 10% or even 20% prob. wont cut it either. This is my view without considering Reba and apo.